[Mechanism of relapse and its therapeutic strategies after allogeneic hematopoietic stem cell transplantation].
作者信息
Wu H W, Zhao Y M, Huang H
机构信息
Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University; Institute of Hematology, Zhejiang University, Hangzhou 310006, China.
出版信息
Zhonghua Xue Ye Xue Za Zhi. 2021 Oct 14;42(10):869-877. doi: 10.3760/cma.j.issn.0253-2727.2021.10.014.
Abstract
摘要
相似文献
1
[Mechanism of relapse and its therapeutic strategies after allogeneic hematopoietic stem cell transplantation].[异基因造血干细胞移植后的复发机制及其治疗策略]
Zhonghua Xue Ye Xue Za Zhi. 2021 Oct 14;42(10):869-877. doi: 10.3760/cma.j.issn.0253-2727.2021.10.014.
2
Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.异基因造血干细胞移植后巨细胞病毒再激活与移植后存活至第100天的急性髓系白血病患者复发风险降低相关：日本造血细胞移植学会移植相关并发症工作组
Biol Blood Marrow Transplant. 2015 Nov;21(11):2008-16. doi: 10.1016/j.bbmt.2015.07.019. Epub 2015 Jul 26.
3
How can we intervene to mitigate post-transplantation relapse in AML? Strategies to mitigate post-transplantation relapse in AML.我们如何干预以减轻 AML 移植后复发？减轻 AML 移植后复发的策略。
Best Pract Res Clin Haematol. 2022 Dec;35(4):101411. doi: 10.1016/j.beha.2022.101411. Epub 2022 Nov 1.
4
Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation: part II. Autologous Transplantation-novel agents and immunomodulatory strategies.美国国立癌症研究所造血干细胞移植后复发的生物学、预防及治疗第二次国际研讨会论文集：第二部分。自体移植——新型药物与免疫调节策略
Biol Blood Marrow Transplant. 2013 Dec;19(12):1661-9. doi: 10.1016/j.bbmt.2013.08.011. Epub 2013 Sep 7.
5
Extramedullary Relapse of Acute Myelogenous Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation.异基因造血干细胞移植后急性髓系白血病髓外复发。
Biol Blood Marrow Transplant. 2019 Jun;25(6):1152-1157. doi: 10.1016/j.bbmt.2019.01.011. Epub 2019 Jan 17.
6
Guest editorial: prophylaxis and treatment of relapse after allogeneic hematopoietic stem cell transplantation.特邀社论：异基因造血干细胞移植后复发的预防与治疗
Int J Hematol. 2022 Sep;116(3):307-308. doi: 10.1007/s12185-022-03407-8. Epub 2022 Jul 11.
7
Outcome of lower-intensity allogeneic transplantation in non-Hodgkin lymphoma after autologous transplantation failure.自体移植失败后低强度异基因移植治疗非霍奇金淋巴瘤的结局。
Biol Blood Marrow Transplant. 2012 Aug;18(8):1255-64. doi: 10.1016/j.bbmt.2011.12.581. Epub 2011 Dec 23.
8
Relapse of lymphoma after allogeneic hematopoietic cell transplantation: management strategies and outcome.异基因造血细胞移植后淋巴瘤复发：管理策略和结果。
Biol Blood Marrow Transplant. 2011 Oct;17(10):1497-504. doi: 10.1016/j.bbmt.2011.02.009. Epub 2011 Feb 18.
9
Monosomal karyotype as an adverse prognostic factor in patients with acute myeloid leukemia treated with allogeneic hematopoietic stem-cell transplantation in first complete remission: a retrospective survey on behalf of the ALWP of the EBMT.单倍体核型作为首次完全缓解期接受异基因造血干细胞移植治疗的急性髓系白血病患者的不良预后因素：代表欧洲血液与骨髓移植协会急性白血病工作组进行的一项回顾性调查
Haematologica. 2016 Feb;101(2):248-55. doi: 10.3324/haematol.2015.132654. Epub 2015 Nov 20.
10
[Clinical outcome of allogeneic hematopoietic stem cell transplantation with FLAG sequential busulfan/cyclophosphamide conditioning regimen for refractory/relapsed acute myeloid leukemia].[采用FLAG序贯白消安/环磷酰胺预处理方案进行异基因造血干细胞移植治疗难治/复发急性髓系白血病的临床结局]
Zhonghua Nei Ke Za Zhi. 2018 Aug 1;57(8):576-581. doi: 10.3760/cma.j.issn.0578-1426.2018.08.008.
本文引用的文献
1
NK cell-based cancer immunotherapy: from basic biology to clinical development.基于自然杀伤细胞的癌症免疫疗法：从基础生物学到临床开发。
J Hematol Oncol. 2021 Jan 6;14(1):7. doi: 10.1186/s13045-020-01014-w.
2
Myeloid-Derived Suppressor Cells in Tumors: From Mechanisms to Antigen Specificity and Microenvironmental Regulation.肿瘤中的髓源性抑制细胞：从机制到抗原特异性和微环境调节。
Front Immunol. 2020 Jul 22;11:1371. doi: 10.3389/fimmu.2020.01371. eCollection 2020.
3
Can Graft vs. Leukemia Effect Be Uncoupled From Graft vs. Host Disease? An Examination of Proportions.移植物抗白血病效应能否与移植物抗宿主病分离？比例研究。
Front Immunol. 2020 Apr 28;11:777. doi: 10.3389/fimmu.2020.00777. eCollection 2020.
4
Mechanisms of Leukemia Immune Evasion and Their Role in Relapse After Haploidentical Hematopoietic Cell Transplantation.白血病免疫逃逸的机制及其在单倍体造血细胞移植后复发中的作用。
Front Immunol. 2020 Feb 25;11:147. doi: 10.3389/fimmu.2020.00147. eCollection 2020.
5
Two unique HLA-A*0201 restricted peptides derived from cyclin E as immunotherapeutic targets in leukemia.两种独特的 HLA-A*0201 限制性细胞周期蛋白 E 肽作为白血病的免疫治疗靶点。
Leukemia. 2020 Jun;34(6):1626-1636. doi: 10.1038/s41375-019-0698-z. Epub 2020 Jan 6.
6
Myeloid-Derived Suppressor Cells in Hematologic Diseases: Promising Biomarkers and Treatment Targets.血液系统疾病中的髓源性抑制细胞：有前景的生物标志物和治疗靶点
Hemasphere. 2019 Jan 28;3(1):e168. doi: 10.1097/HS9.0000000000000168. eCollection 2019 Feb.
7
CIITA-Driven MHC Class II Expressing Tumor Cells as Antigen Presenting Cell Performers: Toward the Construction of an Optimal Anti-tumor Vaccine.CIITA 驱动的 MHC Ⅱ类表达肿瘤细胞作为抗原提呈细胞的执行者：构建优化的抗肿瘤疫苗。
Front Immunol. 2019 Jul 30;10:1806. doi: 10.3389/fimmu.2019.01806. eCollection 2019.
8
Immune signature drives leukemia escape and relapse after hematopoietic cell transplantation.免疫特征驱动造血细胞移植后白血病的逃逸和复发。
Nat Med. 2019 Apr;25(4):603-611. doi: 10.1038/s41591-019-0400-z. Epub 2019 Mar 25.
9
Pretransplant HLA typing revealed loss of heterozygosity in the major histocompatibility complex in a patient with acute myeloid leukemia.移植前HLA分型显示，一名急性髓系白血病患者的主要组织相容性复合体出现杂合性缺失。
Hum Immunol. 2019 Apr;80(4):257-262. doi: 10.1016/j.humimm.2019.02.009. Epub 2019 Feb 19.
10
Molecular and Genetic Characterization of MHC Deficiency Identifies EZH2 as Therapeutic Target for Enhancing Immune Recognition.MHC 缺陷的分子和遗传特征鉴定 EZH2 作为增强免疫识别的治疗靶点。
Cancer Discov. 2019 Apr;9(4):546-563. doi: 10.1158/2159-8290.CD-18-1090. Epub 2019 Jan 31.
Zotero 插件